Only in Titles

Search results for: AntiVEGF

paperclip

Error loading info... Pleas try again later.
paperclip

#34935052   2021/12/22 To Up

Inhibitory effect of miR‑182‑5p on retinal neovascularization by targeting angiogenin and BDNF.

Retinal neovascularization (RNV) is a type of serious vision‑threating disease, commonly induced by hypoxia of ischemic retinopathy, which happens in various ocular diseases including diabetic retinopathy and retinopathy of prematurity. In clinical work, anti‑VEGF therapy is the preferred strategy for treating RNV. However, not all cases are sensitive to anti‑VEGF injection. It is urgent and necessary to develop novel targets for inhibiting neovascularization in ocular diseases. Angiogenin (ANG) and brain‑derived neurotrophic factor (BDNF) are implicated in angiogenesis, although their regulation and effects in RNV remain to be elucidated. microRNA (miRNA) is a type of small non‑coding RNA, which can modulate targets by degrading transcripts or inhibiting protein translation. In the present study, miRNA‑mediated modulation of ANG and BDNF was explored in an oxygen‑induced retinopathy mouse model and human retinal microvascular endothelial cells (HRECs) under hypoxia. The results showed that downregulation of miR‑182‑5p and upregulation of ANG and BDNF were found and . Overexpression of miR‑182‑5p suppressed the expression of ANG and BDNF significantly in HRECs under hypoxia. In addition, knockdown of ANG and BDNF by miR‑182‑5p transfection significantly improved hypoxia‑induced HRECs dysfunctions, including enhancing cell viability, reducing cell migration and improved tube integrity. In conclusion, miRNA‑dependent regulation on ANG and BDNF indicates a critical role in hypoxia‑induced retinal microvascular response. miR‑182‑5p‑based therapy can influence the expression of ANG and BDNF, which demonstrates the potential for treating RNV diseases.
Chenyue Li, Hongxuan Lie, Weifeng Sun

1758 related Products with: Inhibitory effect of miR‑182‑5p on retinal neovascularization by targeting angiogenin and BDNF.

25 mg50ug1 kit(96 Wells)250ul1000 tests100 ul 25 ml Ready-to-use 1000 50ug100.00 ug250 TESTSOne 96-Well Strip Micropl

Related Pathways

paperclip

#34362084   2021/07/27 To Up

Ultrawide Field Imaging in Diabetic Retinopathy: Exploring the Role of Quantitative Metrics.

Ultrawide field imaging (UWF) has allowed the visualization of a significantly greater area of the retina than previous standard approaches. In diabetic retinopathy (DR), significantly more lesions are seen on UWF imaging compared to the seven-standard ETDRS fields. In addition, some eyes have lesions that are located predominantly in the peripheral retina that are associated with an increased risk of DR progression. The current DR severity scales are still largely based on clinically visible retinal microvascular lesions and do not incorporate retinal periphery, neuroretinal, or pathophysiologic changes. Thus, current scales are not well suited for documenting progression or regression in eyes with very early or advanced DR, nor in the setting of vascular endothelial growth factor inhibitors (antiVEGF). In addition, the categorical system is highly subjective, and grading is variable between different graders based on experience level and training background. Recently, there have been efforts to quantify DR lesions on UWF imaging in an attempt to generate objective metrics for classification, disease prognostication and prediction of treatment response. The purpose of this review is to examine current quantitative metrics derived from UWF fluorescein angiograms and UWF color imaging to determine their feasibility in any potential future DR classification.
Mohamed Ashraf, Jerry D Cavallerano, Jennifer K Sun, Paolo S Silva, Lloyd Paul Aiello

1474 related Products with: Ultrawide Field Imaging in Diabetic Retinopathy: Exploring the Role of Quantitative Metrics.

116 Arrays/Slide16 Arrays/Slide 100 UG16 Arrays/Slide

Related Pathways

paperclip

#34336255   2021/07/14 To Up

Characterizing Flow and Structure of Diabetic Retinal Neovascularization after Intravitreal Anti-VEGF Using Optical Coherence Tomography Angiography: A Pilot Study.

/. This study evaluates changes of flow and structure of diabetic retinal neovascularization (NV) treated with intravitreal antivascular endothelial growth factor (VEGF) agents using optical coherence tomography angiography (OCTA). With OCTA, retinal blood vessels are visualized at high resolution to separately look at flow and structure information without the need for dye injection. We introduce a new measurement method including and combining information of flow and structure. . Retrospective observational case series. Patients with proliferative diabetic retinopathy (PDR) were treated with intravitreal antiVEGF injections. Retinal NV were repeatedly imaged using swept-source OCTA (Zeiss PlexElite 9000) at baseline, after initial treatment block with 3-4 monthly injections, and during a follow-up period of up to 51 weeks. Change of size and flow density of the structural and angio area of NV was assessed. . Nine NV in eight eyes of five patients were analyzed with a median follow-up time of 45 weeks. After the initial treatment block, en face structural area regressed, 18.7% ± 39.0% (95% CI 44.2-6.8%, =0.26), and en face angio area regressed, 51.9% ± 29.5% (95% CI 32.6 to 71.2%, =0.007). Flow density within the en face structural area decreased by 33% ± 19.2% (95% CI 20.5-45.5%, =0.0077). Flow density within the en face angio area decreased by mean 17.9% ± 25.2% (95% CI 1.4-34.4%, =0.066). In two fellow eyes, NV recurrence could be observed before the onset of vitreous bleeding in one. . Our study introduces a new quantitative measurement for NV in PDR, combining structure and flow measurement. The structure area remained after treatment, while its flow density and angio area regressed. We propose this measurement method as a more physiological and possibly more comparable metrics.
Christof Haensli, Katrin Fasler, Daniel Barthelmes, Sandrine A Zweifel

1251 related Products with: Characterizing Flow and Structure of Diabetic Retinal Neovascularization after Intravitreal Anti-VEGF Using Optical Coherence Tomography Angiography: A Pilot Study.

100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100 µg100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

#33863263   2021/04/16 To Up

Treatment of neovascular age related macular degeneration during COVID-19 pandemic: The short term consequences of unintended lapses.

To investigate the short-term effects of COVID-19 pandemic related unintended treatment lapses on neovascular age related macular degeneration (nAMD) patients.
Mehmet Ali Sekeroglu, Hilal Kilinc Hekimsoy, Tugce Horozoglu Ceran, Sibel Doguizi

1471 related Products with: Treatment of neovascular age related macular degeneration during COVID-19 pandemic: The short term consequences of unintended lapses.

50 UG 5 G 100 UG2100ug100 μg100 μg100 μg100 μg100 μg100 μg0.1 mg

Related Pathways

paperclip

#33206392   2020/11/17 To Up

Intravitreal steroids for macular edema in diabetes.

Diabetic macular edema (DME) is secondary to leakage from diseased retinal capillaries with thickening of central retina, and is an important cause of poor central visual acuity in people with diabetic retinopathy. Intravitreal steroids have been used to reduce retinal thickness and improve vision in people with DME.
Thanitsara Rittiphairoj, Tahreem A Mir, Tianjing Li, Gianni Virgili

1615 related Products with: Intravitreal steroids for macular edema in diabetes.

1 G 50 UG 1 G 5 G500 MG 100 G250 mg1 mg96 wells (1 kit)

Related Pathways

paperclip

#33099574   2020/10/24 To Up

Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5 colorectal cancer.

In our previous study, ETV5 mediated-angiogenesis was demonstrated to be dependent upon the PDGF-BB/PDGFR-β/Src/STAT3/VEGFA pathway in colorectal cancer (CRC). However, the ability of ETV5 to affect the efficacy of anti-angiogenic therapy in CRC requires further investigation. Gene set enrichment analysis (GSEA) and a series of experiments were performed to identify the critical candidate gene involved in Bevacizumab resistance. Furthermore, the ability of treatment targeting the candidate gene to enhance Bevacizumab sensitivity in vitro and in vivo was investigated. Our results revealed that ETV5 directly bound to the VEGFA promoter to promote translation of VEGFA. However, according to in vitro and in vivo experiments, ETV5 unexpectedly accelerated antiVEGF therapy (Bevacizumab) resistance. GSEA and additional assays confirmed that ETV5 could promote angiogenesis by inducing the secretion of another tumor angiogenesis factor (CCL2) in CRC cells to facilitate Bevacizumab resistance. Mechanistically, ETV5 upregulated CCL2 by activating STAT3 to facilitate binding with the CCL2 promoter. ETV5 induced-VEGFA translation and CCL2 secretion were mutually independent mechanisms, that induced angiogenesis by activating the PI3K/AKT and p38/MAPK signaling pathways in human umbilical vein endothelial cells (HUVECs). In CRC tissues, ETV5 protein levels were positively associated with CD31, CCL2, and VEGFA protein expression. CRC patients possessing high expression of ETV5/VEGFA or ETV5/CCL2 exhibited a poorer prognosis compared to that of other patients. Combined antiCCL2 and antiVEGFA (Bevacizumab) treatment could inhibit tumor angiogenesis and growth more effectively than single treatments in CRCs with high expression of ETV5 (ETV5 CRCs). In conclusion, our results not only revealed ETV5 as a novel biomarker for anti-angiogenic therapy, but also indicated a potential combined therapy strategy that involved in targeting of both CCL2 and VEGFA in ETV5 CRC.
Haoran Feng, Kun Liu, Xiaonan Shen, Juyong Liang, Changgang Wang, Weihua Qiu, Xi Cheng, Ren Zhao

2403 related Products with: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5 colorectal cancer.

1 kit1 kit24 tests1 kit96 samples24 tests24 tests96 samples

Related Pathways

paperclip

#32729025   2020/07/29 To Up

Intravitreal anti‑VEGF agents and cardiovascular risk: comment.


Philip S Rothschild, Penelope L Allen, Joobin Hooshmand, Brendan J Vote

1316 related Products with: Intravitreal anti‑VEGF agents and cardiovascular risk: comment.

5mg100.00 ug1001.00 ml100ug1mg10250ul100ug200.00 ug

Related Pathways

    No related Items
paperclip

#   // To Up


2731 related Products with:



Related Pathways

    No related Items
paperclip

#32616318   2020/06/29 To Up

Corneal endothelial cell density during diabetes mellitus and ocular diabetes complications treatment.

Diabetes mellitus may affect the cornea at various levels. Ocular surface changes and dry eye had been studied. Researchers are concerned that medical treatment of diabetes or retinal complications may result in endothelial damage and cell loss. This report summarizes the possibility of endothelial cell loss in diabetic patients. A decrease in endothelial cell density (ECD) in diabetic patients has been reported. In addition, corneal thickness may increase in diabetic patients. Significant endothelial cell loss has been demonstrated in long-term disease and in cases of poor metabolic control. No association between the use of oral hypoglycemics and ECD has been reported. There is also no evidence of an association between the use of insulin and corneal endothelial damage. No difference in ECD among the various degrees of retinopathy or with a history of photocoagulation has been shown. Regarding the studies comparing diabetic and non-diabetic patients undergoing cataract surgery, in all cases, the decrease in ECD is higher in diabetic patients than that seen in non-diabetic patients. However, there is no evidence of increased endothelial damage in diabetics compared to non-diabetics during vitreo-retinal surgery in phakic eyes. No significant changes in corneal endothelium after intravitreal anti-VEGF injections have been referenced.
C Pont, F J Ascaso, A Grzybowski, V Huerva

1802 related Products with: Corneal endothelial cell density during diabetes mellitus and ocular diabetes complications treatment.

1.00 flask1.00 flask1.00 flask1.00 flask 6 ml Ready-to-use 1.00 flask1.00 flask1.00 flask0.1 mg1.00 flask

Related Pathways